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Abstract
We consider estimating the “de facto” or effectiveness estimand in a ran-
domised placebo-controlled or standard-of-care-controlled drug trial with quan-
titative outcome, where participants who discontinue an investigational treat-
ment are not followed up thereafter. Carpenter et al. (2013) proposed reference-
based imputation methods which use a reference arm to inform the distri-
bution of post-discontinuation outcomes and hence to inform an imputation
model. However, the reference-based imputation methods were not formally
justified. We present a causal model which makes an explicit assumption in
a potential outcomes framework about the maintained causal effect of treat-
ment after discontinuation. We show that the “jump to reference”, “copy
reference” and “copy increments in reference” reference-based imputation
methods, with the control arm as the reference arm, are special cases of the
causal model with specific assumptions about the causal treatment effect.
Results from simulation studies are presented. We also show that the causal
model provides a flexible and transparent framework for a tipping point sen-
sitivity analysis in which we vary the assumptions made about the causal
effect of discontinued treatment. We illustrate the approach with data from
two longitudinal clinical trials.
1 Introduction
Missing outcome data represent a major threat to the validity of randomised
clinical trials (RCTs), and appropriate analysis methods have been much
discussed. An influential report showed that different analysis methods may
target different estimands (different measures of treatment effect) and ar-
gued that specification of the estimand is an important part of trial design
and should inform trial analysis and reporting (National Research Council,
2010). Regulators have joined the call for estimands to be defined clearly
(ICH steering committee, 2014).
Estimands have long been discussed in the causal inference literature.
For example, Angrist et al. (1996) discussed all-or-nothing non-compliance
in RCTs and gave conditions under which instrumental variable methods es-
timate the complier-average causal effect (CACE), that is, the mean effect of
treatment in those who will receive treatment if and only if they are assigned
to treatment. This differs from the intention-to-treat estimand which is the
mean effect of allocation to treatment. In general, the estimand can be de-
signed to take into account or not take into account potential confounding
of the data by post-randomisation events such as non-compliance, discontin-
uation of intervention, treatment switching, or use of rescue medication.
We consider two types of estimand considered by National Research Council
(2010): (E1) difference in outcome improvement at the planned endpoint if
all participants had tolerated or adhered to trial protocol; (E2) difference
in outcome improvement at the planned endpoint for all randomised par-
ticipants. The former measures how treatment works in an ideal setting
(efficacy), while the latter measures how treatment might work in practice
(effectiveness). To encompass outcomes that measure harms of treatment,
Carpenter et al. (2013) proposed the broader terms de jure and de facto es-
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timand for (E1) and (E2) respectively.
Sometimes investigators continue to collect data after treatment discon-
tinuation, which we call “off-treatment data”. The use of such data depends
on the estimand (Permutt, 2016). For the estimation of a de jure estimand,
off-treatment data for participants who discontinued randomised treatment
could be used in a CACE analysis (Dunn et al., 2003). In practice, however,
off-treatment data are typically either not collected or are excluded from the
primary analysis, and the missing data are assumed to be missing at random
(MAR): that is, it is assumed that participants who discontinued treatment
would have benefited from continued treatment in the same way as those who
remained on treatment. However, estimation of a de facto estimand ideally
makes use of the off-treatment data, and guidance recommends its collection
where possible (National Research Council, 2010). When all discontinuers
are followed up and outcome data obtained, the de facto estimand can be
directly estimated by comparing observed means (Little and Kang, 2015).
This paper considers estimation of a de facto estimand for a quantitative
outcome in the absence of off-treatment data. This requires assumptions
about how participants who have discontinued treatment benefit from their
previous treatment. For example, participants who received only a partial
period of treatment may not have benefited after treatment discontinua-
tion in a similar manner to those who completed the treatment in the trial.
We also focus on the situation in which rescue treatment (over and above
the per protocol treatment regime for the control arm) for those who dis-
continue randomised treatment is not available, or interest is in the effect
attributable to the initially randomised treatment without the confounding
effects of rescue medications (where the latter corresponds to estimand 6 in
Mallinckrodt et al. (2012)).
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In previous work on this topic, Little and Yau (1996) presented a multi-
ple imputation (MI) approach that can incorporate a variety of alternative
assumptions about treatment dose after treatment discontinuation for the
estimation of de facto estimands in RCTs. Carpenter et al. (2013) presented
a generic algorithm for MI of post-discontinuation outcome data. They de-
rived the conditional distribution of post-discontinuation outcome data given
pre-discontinuation outcome data and time of discontinuation from a joint
Normal distribution which could be formed with reference to other arms in
several ways. For the “copy reference” (CR) method, the mean of the joint
distribution is taken as the mean for the reference arm. For other meth-
ods, the mean of the joint distribution in a specific arm follows the mean of
that arm until treatment discontinuation; after treatment discontinuation,
it is formed either by directly using the means over time for the reference
arm (the “jump to reference” (J2R) method); by using the mean in the spe-
cific arm at the time of treatment discontinuation (the “last mean carried
forward” (LMCF) method); or by using the mean for the specific arm at
the time of treatment discontinuation plus the mean increments over time
in the reference arm (the “copy increments in reference” (CIR) method).
The variance-covariance matrix of the joint distribution is set equal to the
variance-covariance matrix from either the active (investigational) treatment
arm or the reference arm. However, Carpenter et al. (2013) did not pro-
vide a theoretical justification of these “reference-based imputation” (RBI)
methods.
Specification of estimands is clarified by using counterfactual outcomes –
outcomes that have not or could not have been observed. Such counterfactu-
als are best described using potential outcomes notation (Little and Rubin,
2000; Angrist et al., 1996). Our aims in this paper are to provide mathemat-
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ical derivation of the RBI methods, including their identifying assumptions,
in a potential outcomes framework, and to propose a post-discontinuation
imputation model using explicit causal assumptions to enable generalization
of the RBI methods. We do this by assuming that after discontinuing their
randomised treatment, participants receive treatment that is similar to that
allocated to the control arm: thus in the case of reference-based imputation,
we take the reference to be the control treatment, where this is typically
either placebo or standard of care (SoC). Further, while we allow both a
delayed response to the active treatment and a maintained response after
discontinuing the active treatment, we implicitly assume that there is no de-
layed response to the control treatment: thus when a patient discontinues
randomised treatment, we assume the effects of any treatments they switch
to are similar to the effects they would have experienced had they received
the control treatment from the start of the trial.
Since the imputation models in our proposal rely on untestable assump-
tions, sensitivity analyses are desirable for understanding the impact of the
assumptions on inferences and conclusions from the primary analysis. Kenward et al.
(2001) described a principled approach to sensitivity analyses which varies
a sensitivity parameter that quantifies deviations from the missing data
assumption. A tipping point sensitivity analysis (e.g. Yan et al. (2009);
Liublinska and Rubin (2014)) extends this approach by varying the sensitiv-
ity parameter until the conclusion from the primary analysis is overturned.
In this paper, we propose a tipping point sensitivity analysis using the causal
model.
In Section 2, we investigate the underlying assumptions for RBI methods
and present a causal model that requires an explicit assumption on post-
discontinuation behaviour in terms of the average treatment effect which is
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maintained after treatment discontinuation. In Section 3, we demonstrate
the equivalence of RBI and causal model estimates in a simulation study. In
Section 4, we illustrate the proposed approach and demonstrate the tipping
point analysis with two example data sets. We conclude with summary
remarks in Section 5.
2 RBI methods and causal model
Our aim here is to propose a causal model which can be used to impute
missing values, and to relate the mean imputations from the causal model
to the mean imputations derived under RBI. We start by presenting nota-
tion and estimands, and then present the assumptions used in imputation, a
comparison of the methods, and details of implementation.
2.1 Notation and simplifying assumptions
We consider a two-arm longitudinal RCT with tmax scheduled observation
times after randomisation. Let Z denote the randomised treatment arm with
Z = a for the active treatment and Z = c for the control treatment. Let
Yt denote the outcome at the tth observation time, where t = 0, 1, ..., tmax
and t = 0 denotes the baseline observation. Each Yt may be observed or
missing; if missing, it is the value of the actual outcome that is experienced
by the participant despite being unobserved by the investigators. Let Y =
(Y0, ..., Ytmax)
′
denote the vector of all outcomes, with subvectors Y ≤t =
(Y0, ..., Yt)
′
for outcomes until time t (including the baseline), and Y >t =
(Yt+1, ..., Ytmax)
′
for outcomes after time t. We assume for clarity that the
only baseline covariate is the baseline value of the outcome, Y0, but other
baseline covariates can be accommodated by replacing Y0 with a baseline
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covariate vector Y 0.
We assume that individuals in both arms may discontinue their ran-
domised treatment during the course of follow-up, but they do not restart
treatment. We let Da, 0 ≤ Da ≤ tmax, denote the last observation time for
an active arm participant prior to stopping treatment, and similarly for Dc
in the control arm. Da or Dc = tmax denotes a participant who continues
treatment throughout the trial. We assume that, by the design of the trial,
there is no follow-up after treatment discontinuation, and that data may also
be intermittently missing before treatment discontinuation.
We define the potential outcome Yt(s), for 0 ≤ s, t ≤ tmax, as the true
outcome at time t if the active treatment were received for s periods and then
control treatment were received. We assume that outcomes are not causally
affected by future treatment, so
Yt(s) = Yt(t) for all s > t. (1)
In particular, (1) means that the baseline value is unaffected by treatment,
Y0(s) = Y0 for all s. All counterfactual outcomes Yt(s) are assumed to
be independent of Z (by randomisation), but not of Da or Dc (treatment
discontinuation may be related to counterfactual outcomes). Let Y (s) =
(Y0(s), ..., Ytmax(s))
′
with subvectors Y ≤t(s) = (Y0(s), ..., Yt(s))
′
and Y >t(s) =
(Yt+1(s), ..., Ytmax(s))
′
. The overall means of counterfactuals are defined as
µ(s) = E [Y (s)], µ≤t(s) = E [Y ≤t(s)] and µ>t(s) = E [Y >t(s)].
Finally, let the variance-covariance matrices be Σ(s) = var (Y (s)) for
s = 0 or tmax, with submatrices Σ≤t≤t(s), Σ>t≤t(s), Σ≤t>t(s), Σ>t>t(s). For
the linear regression of Y >t(s) on Y ≤t(s), we write the regression coefficients
as βt(s) = Σ>t≤t(s)Σ≤t≤t(s)
−1 and the residual variance as Σ>t>t|≤t(s) =
Σ>t>t(s)−Σ>t≤t(s)Σ≤t≤t(s)
−1Σ≤t>t(s). The notation is summarised in Table
1.
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[TABLE 1 ABOUT HERE.]
2.2 Estimands
Given this notation, we can write the de jure estimand (estimand E1) at
time t > 0 as E[Yt(t) − Yt(0)]. The de facto estimand (estimand E2) is the
estimand of interest in this paper and is defined as E[Yt(Da)−Yt(0)]. Often,
primary interest is in the last observation time, t = tmax.
2.3 Imputation
Our aim is to impute Y >t(t) in the Da = t subgroup where t < tmax. Because
our main concern is bias, we focus on the mean of the imputation distribution.
Variances are considered in Section 2.5.
2.3.1 Initial assumptions and modelling
Assumption A1. (Y |Z = c) is missing at random (MAR).
Assumption A1 states that the observed outcomes in the control arm are
MAR. If there are no missing data before treatment discontinuation then we
can also write this
p(Dc = t|Z = c,Y , Dc ≥ t) = p(Dc = t|Z = c,Y ≤t, Dc ≥ t)
for all t. In other words, treatment discontinuation in the control arm does
not depend on future (untreated) outcomes, given the past and present.
Assumption A2. (Y (tmax)|Z = a) is MAR.
Assumption A2 states that the counterfactual fully treated outcomes up
to time t in the active arm are MAR. If there are no missing data before
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treatment discontinuation then we can also write this
p(Da = t|Z = a,Y (tmax), Da ≥ t) = p(Da = t|Z = a,Y ≤t(tmax), Da ≥ t)
for all t. In other words, treatment discontinuation in the active arm does
not relate to future fully-treated outcomes, given the past and present.
We do not assume that the actual outcomes in the active arm, (Y |Z =
a), are MAR. Indeed, this is unlikely to be true, since (if treatment works)
treatment discontinuation causally affects actual future outcomes. Thus
treatment discontinuation is allowed to relate to future actual outcomes,
given the past and present.
Assumption A1 allows us to estimate µ(0) andΣ(0) by applying likelihood-
based methods to the observed outcomes in arm Z = c. Assumption A2 al-
lows us to estimate µ(tmax) and Σ(tmax) by applying likelihood-based meth-
ods to the observed outcomes in arm Z = a. These two assumptions are
therefore enough to identify the de jure estimand. They also allow us to
impute intermittent missing data before treatment discontinuation in the ac-
tive treatment arm, and all missing data in the control arm, so henceforth
we assume that the only missing data are actual outcomes after treatment
discontinuation in the active arm.
2.3.2 Post-discontinuation imputation using explicit causal assump-
tions
For the de facto estimand, we need to impute actual outcomes after treat-
ment discontinuation. We consider an individual in the active arm who stops
treatment at time t < tmax with history Y ≤t. We use as imputation model
a multivariate linear regression model with variance-covariance matrix de-
scribed in Section 2.5. We write the mean in this model as the sum of three
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terms:
E[Y >t(t)|Z = a,Y ≤t, Da = t] = {E[Y >t(t)|Z = a,Y ≤t, Da = t]− µ>t(t)}
+ {µ>t(t)− µ>t(0)}+ µ>t(0) (2)
where the first term represents the difference between the subgroup who
discontinue at time t and the whole group (“selection term”), the second term
represents the treatment effect in the whole group (“maintained treatment
effect”), and the third term is the mean in the control arm. The third term is
identified by assumption A1, and we make the identifying assumptions below
for the first two terms on the right hand side of (2).
2.3.3 Selection term
To identify the first term in (2), we assume
Assumption A3. Y >t(t)|Y ≤t(t) follows a linear regression for each t.
Assumption A4. p(Da = t|Z = a,Y (t)) = p(Da = t|Z = a,Y ≤t(t)).
A4 appears similar to A2, but whereas A2 states that treatment discon-
tinuation at time t is unaffected by future fully-treated potential outcomes,
A4 refers instead to future partly-treated potential outcomes. If there are no
missing data before treatment discontinuation then a stronger assumption
which implies both A2 and A4 is
p(Da = t|Z = a,Y (s), Da ≥ t) = p(Da = t|Z = a,Y ≤t(s), Da ≥ t)
for all t and all s > t.
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We can now write the selection term as
E [Y >t(t)|Z = a,Y ≤t(t), Da = t] − µ>t(t)
= E [Y >t(t)|Z = a,Y ≤t(t)] − µ>t(t) (by A4)
= E [Y >t(t)|Y ≤t(t)] − µ>t(t) (by randomisation)
= βt(t)
{
Y ≤t(t)− µ≤t(t)
}
(by A3) (3)
where βt(t) is the matrix of regression coefficients of Y >t(t) on Y ≤t(t) and
is not yet identified. However βt(0), the regression of Y >t(0) on Y ≤t(0), and
βt(tmax), the regression of Y >t(tmax) on Y ≤t(t), are identified by assumptions
A1 and A2 respectively. If all treatment effects are homogeneous (i.e. if
Y (t) − Y (0) does not vary between individuals for any t) then βt(t) =
βt(tmax) = βt(0). Otherwise, they typically differ. Often, we may be willing
to assume that Σ(tmax) = Σ(0), in which case βt(tmax) = βt(0) and this
is clearly a sensible choice for βt(t). More generally we propose assuming
either βt(t) = βt(tmax) or βt(t) = βt(0).
2.3.4 Maintained treatment effect
To identify the second term in (2), we make an explicit assumption about
the maintained effect of treatment after discontinuation:
Assumption A5. E [Y >t(t)− Y >t(0)] =KtE [Y ≤t(t)− Y ≤t(0)]
or equivalently
µ>t(t)− µ>t(0) =Kt
{
µ≤t(t)− µ≤t(0)
}
(4)
where Kt is a (tmax − t)× (t+ 1) matrix of sensitivity parameters: it is not
identified by the data and must be specified by the user. µ≤t(0) and µ≤t(t)
are identified by assumptions A1 and A2, respectively.
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Equation (1) implies µ0(t) − µ0(0) = 0 so the first column of Kt does
not affect equation (4) and need not be defined. In most cases the post-
discontinuation treatment effect depends only on the treatment effect at the
time of discontinuation and not on treatment effects at earlier times, and
therefore Kt needs to have non-zero elements only in the final column: our
software implementation below relies on this assumption. For tipping point
sensitivity analyses, we consider two causal models with just one parameter
in Kt:
E [Ys(t)− Ys(0)] = k0E [Yt(t)− Yt(0)] (5)
E [Ys(t)− Ys(0)] = k
vs−vt
1 E [Yt(t)− Yt(0)] (6)
for s > t, where vs, vt are the times (on a suitable scale) of observations s, t.
The maintained treatment effect after treatment discontinuation is constant
in model (5) but decays exponentially in model (6), being multiplied by k1
in every period, where 0 ≤ k1 ≤ 1. A combined model is
E [Ys(t)− Ys(0)] = k0k
vs−vt
1 E [Yt(t)− Yt(0)] . (7)
2.4 Comparison with reference-based imputation in ac-
tive arm
For imputing Y >t(t), Carpenter et al. (2013, 2014) specified four conditional
distributions of post-discontinuation outcomes given pre-discontinuation out-
comes under assumptions A1, A2 and A3. The means of these imputation dis-
tributions in potential outcomes notation are given in Table 2 for the Da = t
subgroup for any t < tmax. In Table 2,C t is a ‘carry-forward’ (tmax−t)×(t+1)
matrix containing t columns of zeroes and a final column of ones, so that
C tµ≤t(t) is a column vector containing tmax − t copies of µt(t). The expres-
sion for CR would usually be written βt(0)
{
Y ≤t − µ≤t(0)
}
+µ>t(0) but has
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been expanded here to demonstrate similarity with the other expressions.
The corresponding expression for the causal model is derived by substituting
equations (3) and (4) into (2) and is given in the last row of Table 2.
[TABLE 2 ABOUT HERE]
In these expressions, the first term again represents a selection effect de-
scribing how an individual with Da = t differs systematically from the whole
group. The second term represents the effect of treatment up to time t (com-
pared with not receiving the active arm treatment at all) on the outcome,
except for LMCF. From Table 2, it is clear that RBI methods other than
LMCF correspond to particular choices of Kt with βt(t) = βt(0): Kt = 0
for J2R, Kt = C t for CIR, and Kt = βt(0) for CR. This makes precise the
statement of Mallinckrodt et al. (2012) that, under CIR, CR and J2R, the
Da = t subgroup have the treatment effect at time t maintained, diminished
and eliminated respectively at time tmax. The LMCF method does not cor-
respond to the causal model. Table 2 assumes that the variance-covariance
matrix is taken from the control arm; it could also be taken from the ac-
tive treatment arm, in which case the same equivalences apply, but with
βt(t) = βt(tmax).
A useful expression (derived in Appendix A) for the de facto estimand at
time tmax is
E[Ytmax(Da)− Ytmax(0)] = αtmaxδtmax +
∑
t<tmax
αte
′
tKtδt
+
∑
t<tmax
αte
′
t
(βt(t)− βt(tmax))E [Y ≤t(t|Da = t)− Y ≤t(t)] (8)
where αt = p(Da = t) expresses the discontinuation distribution in the
active treatment arm; δt = E [Yt(t)− Yt(0)] is the de jure estimand, with
δ0 = 0; δt = (δ0, δ1, . . . , δt)
′; and et = (0, ..., 0, 1)
′ of length tmax − t.
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Similar expressions apply at times t < tmax. From (8), the bias in the
de facto estimate associated with wrongly assuming βt(t) to equal β˜t(t) is
∑
t<tmax
αte
′
t
(β˜t(t) − βt(t))E [Y ≤t(t|Da = t)− Y ≤t(t)], and the bias associ-
ated with wrongly assuming Kt to equal K˜t is
∑
t<tmax
αte
′
t(K˜t −Kt)δt.
2.5 Implementation of the causal model
2.5.1 Option 1: directly using the SAS 5 macros
The SAS 5 macros were developed by James Roger to perform multiple im-
putation under the RBI methods and are available at the web page (on
www.missingdata.org.uk) of the DIA working group for missing data. We
modified the Part2A macro to impute under the causal model with
Kt = kCt (9)
where k is a scalar that may vary between participants. This enables causal
model (5) to be implemented by setting k = k0, the same for all partici-
pants. When interest is in the outcome at time tmax, causal model (6) can
be implemented by setting k = ktmax−Da1 , which varies across participants
with different values of Da. The modified macro is available on the DIA
working group web page and sample code is provided in Appendix B. By
default the variance-covariance matrices in the two arms, Σ(tmax) and Σ(0),
are assumed equal, but the user can specify them to be unequal, which is the
case we consider.
2.5.2 Option 2: indirectly using the SAS 5 macros (based on J2R)
Equation (8) for the de facto estimand at time tmax can be written as
E[Y tmax(Da)− Y tmax(0)] = δJ2R +
∑
t<tmax
αte
′
t
Ktδt
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where δJ2R is the J2R estimand. Thus we can run the J2R method to estimate
the first term, fit a mixed model for repeated measures to estimate the δt,
directly estimate the αt, and assume values for Kt.
To approximate the standard error, we propose using the Rubin’s rule
(RR) estimate of standard error from J2R, as we will see in Section 3 that
the standard error does not vary much with Kt.
2.5.3 Option 3: using Mixed Model Repeated Measures (MMRM)
estimates or standard Multiple Imputation (MI)-based es-
timates
If we are willing to assume either that βt(t) = βt(tmax) or that there is no
selection effect, then the third term in expression (8) vanishes and the de
facto estimand at time tmax can be written as
E[Y tmax(Da)− Y tmax(0)] = αtmaxδtmax +
∑
t<tmax
αte
′
t
Ktδt.
That is, the de facto estimate at time tmax can be estimated as a linear
combination of de jure MAR-based estimates at times t ≤ tmax. To find the
standard error, we could ignore uncertainty in the αˆt and use the standard
error of the linear combination, or we could do better by applying the delta
approximation method (Oehlert, 1992) as done by Liu and Pang (2016).
3 Simulation
We performed a simulation study to demonstrate equivalence of the RBI
methods and the proposed causal model for estimating the treatment effect
at the final time point, and to assess the impact of mis-specification of Kt
and βt(t).
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3.1 Design
We consider a RCT with one baseline observation and two post-baseline
follow-ups during the treatment period (that is, tmax = 2). Potential un-
treated outcomes Y (0) in both arms were generated from a multivariate
normal (MVN) distribution with mean µ(0) = (10, 12, 14)
′
and variance-
covariance matrix AR(1) with standard deviation 3 and lag-one correlation
0.5. Potential fully-treated outcomes were derived using the causal models
Y1(1) − Y1(0) = δ1 + u1 and Y2(2) − Y2(0) = δ2 + u1, where δ1 = 1 and
δ2 = 2 are average treatment effects and u1 may vary between participants
to give treatment effect heterogeneity. In the control arm, we assumed that
all participants had complete data. Observed outcomes in the control arm
were set equal to untreated potential outcomes.
In the active arm, we assumed that participants either completed the
entire period of treatment and provided complete measurements (Da = 2),
or completed only the first period of treatment and failed to provide mea-
surements at visit 2 (Da = 1). The treatment discontinuation mechanism
was logit p(Da = 1|Y0, Y1(1)) = τ0 + τ1Y1(1). Observed outcomes were set
equal to the potential fully-treated outcomes. We used two values of τ1: 0
for missing completely at random (MCAR) and 1 for MAR. τ0 was chosen
to give p(Da = 1) = 0.5.
We explored the implications of differences between βt(tmax) and βt(0).
Since missing data occur only in the Da = 1 group, we needed only consider
differences for t = 1, that is, between β1(2) and β1(0). The distribution
above for Y (0) implies β1(0) = (0, 0.50)
′. We used two treatment effect
models: homogeneity, u1 = 0 implying β1(2) = (0, 0.50)
′ = β1(0); and
heterogeneity, u1 ∼ N(0, 2.5
2) implying β1(2) = (−0.12, 0.74)
′ 6= β1(0). The
latter model resulted in slightly more heterogeneity in the active arm than in
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the control arm. We considered 250 participants per arm and 1000 repetitions
for the simulation study.
This completes the mechanism for simulating the observed data. How-
ever, the de facto estimand depends on the unobserved data including the
potential partly-treated outcomes Y2(1) whose distribution has not yet been
specified. We generated Y2(1) from the causal model Y2(1)−Y2(0) = kδ1+u2
where k took values 0, 0.5, 0.74 or 1, and where the marginal distribution
of u2 was the same as that of u1 with either (a) corr(u1, u2) = 0.5, so that
β1(1) = β1(0), or (b) corr(u1, u2) = 1, so that β1(1) = β1(2). For the
treatment effect homogeneity model, options (a) and (b) are equivalent.
For each mechanism for simulating the observed data, we analysed the
data in three ways. Firstly (reported in panel A of Tables 3 and 4), we
generated the complete data by setting Y2 = Y2(Da) under the various values
of k and the two choices of β1(1) described above, and analysed the complete
data. Secondly (reported in panel B of Tables 3 and 4) we imputed the
missing data using the causal model. Here K1 was a 1× 2 vector whose first
element was irrelevant and whose second element was the scalar k. Using k˜
and β˜1(1) to denote assumed values of k and β1(1), we took the same range of
values for k˜ as proposed for k above, and the same choices of β˜1(1). Thirdly
(reported in panel C of Tables 3 and 4) we imputed the missing data using the
reference-based imputation methods CR, CIR and J2R with the two choices
of variance-covariance matrix. In all cases, we estimated the treatment effect
from a linear regression of Y2 on randomised arm and baseline Y0. With
imputed data, standard errors were computed using Rubin’s rules.
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3.2 Results
Table 3 displays the average estimated treatment difference at the final visit
for each data generating mechanism.
Comparing panels A and B shows that the causal model imputation meth-
ods result in unbiased estimates when the assumed values of β˜1(1) and k˜ agree
with the true values of β1(1) and k.
Comparing panels B and C shows that the RBI estimates with variance-
covariance matrix drawn from the control arm are special cases of the causal
model estimates with β1(1) = β1(0), and the RBI estimates with variance-
covariance matrix drawn from the active arm are special cases of the causal
model estimates with β1(1) = β1(2). Specifically, J2R corresponds to k˜ = 0,
CIR corresponds to k˜ = 1, and CR corresponds to k˜ = the second element
of β1(1) which is 0.50 or 0.74 depending on the data generating mechanism.
Comparing different choices of β˜1(1) when the observed data had either
no selection effect (i.e. under MCAR) or β1(0) = β1(2) (that is, in the first
three data generating mechanisms), we see that choice of β˜1(1) does not
affect estimates, as expected from Section 2.4. Sensitivity to choice of β˜1(1)
was observed in the fourth data generating mechanism (MAR with β1(0) 6=
β1(2)): mean causal model estimates were reduced by 0.29 by assuming
β1 = β1(0) instead of β1 = β1(2). Sensitivity to choice of k˜ was the same
for all values of β1 (see Section 2.4): for example, assuming k˜ = 0 instead of
k˜ = 1 reduced mean causal model estimates by 0.50 irrespective of the value
of β1.
[TABLE 3 ABOUT HERE]
Table 4 displays the average standard error (SE) (the average of the
1000 SEs) and the empirical SE (the sample standard deviation of the 1000
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point estimates) for the treatment difference at the final visit. Empirical and
average SEs for J2R and CIR are similar to those for corresponding causal
model estimates. The SEs for CR are slightly larger than that for causal
model with k˜ = the second element of β1 because k˜ is an assumed value
while β1 is estimated. With MAR data, the larger average and empirical
SEs due to using the variance-covariance matrix from the active arm rather
than from the control arm is mainly because of no missing data in the control
arm and larger heterogeneity in the active arm than in the control arm.
More importantly, as shown in Seaman et al. (2014), the results confirm that
both RBI and causal model methods give (1) smaller empirical SEs than the
estimator based on the complete data, and (2) larger average SEs (estimated
using RR) than the empirical SEs of the methods and the empirical SEs based
on the complete data. We comment on these observations in the discussion.
[TABLE 4 ABOUT HERE]
4 Examples
We use two example data sets from randomised, double blind, parallel-group
studies comparing active drug with placebo. The first is from a trial of 172
participants with major depressive disorders, taken from the DIA page of
www.missingdata.org.uk, and used in the DIA working group to demonstrate
various missing data related analytical methods. The outcome variable is the
17-item Hamilton Depression Rating Scale, HAMD17. The second, kindly
supplied by Devan Mehrotra, is from a pain trial with a pain score as outcome.
In the HAMD17 trial, 76% (64/84) and 74% (65/88) of randomised par-
ticipants completed the final (fourth) visit in the drug and the placebo arms
respectively. In the pain score trial, the completion rate at the final (sixth)
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visit was 70% (47/67) and 67% (36/54) in the drug and the placebo arms
respectively. In both trials, participants were not followed up after treat-
ment discontinuation. The observed trajectory means and the frequency of
dropout patterns in each trial are shown in Figure 1.
[FIGURE 1 ABOUT HERE]
We used the SAS 5 macros for implementing the RBI and the causal
models (Section 2.5.1). For the RBI methods, we assumed participants in
the drug arm were treated similarly to the placebo arm after discontinuing
the drug. To construct the joint distribution of pre- and post-discontinuation
drug-arm data under the RBI methods, we first used the variance-covariance
matrix from the placebo arm (RBI1 analyses) and then repeated the methods
with the variance-covariance matrix from the drug arm (RBI2 analyses).
Table 5 shows the estimated treatment effect on HAMD17 and pain score
at the final visit from standard MI, MMRM and RBI methods. The standard
MI and MMRM methods estimate the de jure estimand. These differ slightly
for HAMD17 because of a small incompatibility between the imputation and
analysis models: the imputation model used all visits to estimate a common
the effect of the baseline covariate PoolInv, but the analysis model used
only the final visit. The RBI methods estimate the de facto estimand and
showed, as expected, treatment estimates of smaller magnitude than the de
jure estimand, with J2R giving the smallest magnitude of treatment effect
followed by CR. Using the variance-covariance matrix from the drug arm
rather than from the placebo arm gave slightly more conservative estimates.
[TABLE 5 ABOUT HERE]
We demonstrate tipping point sensitivity analyses using causal models
(5) and (6). In model (5), a fraction k0 of the treatment effect is maintained
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at all times after discontinuation. Figure 2 shows the de facto estimates and
95% CI over a range of k0 from -0.5 to 2.5. As shown in the theory and the
simulation results, the J2R and CIR estimates correspond to using the causal
model with k0 = 0 (i.e., when participants in the active arm lost their treat-
ment effect after the discontinuation) and k0 = 1 (i.e., when participants in
the active arm maintained their treatment effect after the discontinuation),
respectively. Values k0 < 0 mean that the effect of treatment after discon-
tinuation is harmful, while values k0 > 1 mean that the effect of treatment
after discontinuation is greater than before discontinuation. The tipping
point analysis on HAMD17 shows that statistical significance is lost when
k0 < 0 (with variance-covariance from the placebo arm) or k0 < 0.05 (with
variance-covariance from the active arm). In both cases, this suggests that
the de facto estimate of treatment effect on HAMD17 is non-significant only
if any benefit of the active treatment is lost immediately following discontin-
uation. For the pain score, statistical significance is lost when k0 < 1.1 or
k0 < 1.3 (depending on whether the variance-covariance matrix is taken from
the placebo or the drug arm, respectively). This suggests that, in order for
the de facto estimate of treatment effect to be statistically significant, there
would need to be a delayed benefit such that the treatment effect was greater
after discontinuation than before discontinuation. In both trials, comparing
Table 5 with Figure 2 shows that the MAR analyses give estimates of the de
jure estimand that are numerically similar to the causal model estimates of
the de facto estimand when values around k0 = 2 are assumed.
[FIGURE 2 ABOUT HERE]
In model (6), the treatment effect decays exponentially after discontin-
uation. Here, k1 = 0 for J2R and 1 for CIR. Figure 3 shows the de facto
20
estimates of treatment effect at the final visit and its 95% CI from the causal
model over a range of k1. This model does not accommodate the effect of
treatment after discontinuation being either harmful or greater than before
discontinuation, and because of the more limited range of k1, the tipping
point is not reached: all results are statistically significant for HAMD17 and
not significant for the pain score.
[FIGURE 3 ABOUT HERE]
5 Discussion
We have considered longitudinal RCTs with quantitative outcomes in which
participants who discontinue an active treatment are not followed up there-
after, but are assumed to receive a standard treatment which is often the
control treatment. We have focused on estimating the effect of assignment
to treatment in the actual treatment circumstances of the trial (de facto es-
timand) rather than the treatment effect if all participants had tolerated or
adhered to trial protocol (de jure estimand). We have investigated the un-
derlying assumptions of the RBI methods and proposed a generalised causal
modelling approach to account for treatment discontinuation in the estima-
tion of the de facto estimand. The proposed causal model makes an explicit
assumption about the causal effect of a given treatment history, and provides
flexibility to perform sensitivity analyses to the causal assumption.
The proposed causal model specifies how much of the treatment effect
is maintained after treatment discontinuation, which we represent by the
parameter matrixKt. We illustrated this with two examples ofKt: (5) with
the maintained treatment effect independent of time since discontinuation,
and (6) with the maintained treatment effect decaying exponentially with
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visits since discontinuation. A simple extension would allow Kt to depend
on the reason for treatment discontinuation. Ideally sponsors should justify
the choice of Kt in the trial protocol based on the nature of the trial and
the treatments.
The choice of βt(t) (reflecting within-subject dependence of post-discontinuation
outcomes on pre-discontinuation outcomes) should similarly be pre-specified;
it is hard to recommend a single choice and perhaps both βt(t) = βt(0) and
βt(t) = βt(tmax) should be implemented. If the analyst is willing to as-
sume equal variance-covariance matrices across trial arms then the situation
is simpler and βt(t) = βt(0) = βt(tmax) is the obvious choice.
Our model has been presented for the case of active arm treatment discon-
tinuation, where subjects who discontinue do not then receive rescue medica-
tion (in the case of placebo controlled trials), or only receive standard of care
(in the case where the control arm is standard of care). It can be extended to
handle the control arm starting active treatment: an assumption like A5 still
holds, but the Kt matrix must be replaced by assumptions about how the
treatment effect builds up over time. We are currently working on extending
the model to trials comparing two active treatments. An unresolved problem
is how to handle initiation of rescue medications.
We have focussed on varying assumption A5, but we should also assess a
number of other assumptions. The MAR assumptions A1 and A2, and the
related assumption A4, could be made more plausible if the model could
be extended to include further time-dependent covariates. Alternatively
one could explore sensitivity to these assumptions by methods like those
of Ratitch et al. (2013). It is less clear how to assess departures from the
linearity assumption A3.
We have focussed on quantitative outcomes. Extension to other outcomes
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would be useful, and we are currently working on a causal version of the
method of Keene et al. (2014) for recurrent events.
We proposed approximations to the RR variance in options 2 and 3 of Sec-
tion 2.5. From the simulation and empirical results, we see that the SEs are
not much affected by the value of Kt. This means that our approximations
are adequate if we want the RR variance but not if we want the repeated sam-
pling variance. The repeated sampling variance of the estimated treatment
effect tends to be smaller than the RR estimate of variance for a given Kt.
The repeated sampling variance can be approximated in practice using the
delta method (Oehlert, 1992; Liu and Pang, 2016). Carpenter et al. (2014)
argue that the repeated sampling variance is not appropriate, since it is typ-
ically smaller than the complete-data variance (to an extent which strongly
depends on the value of Kt). They also argue that the RR estimate of vari-
ance of the treatment effect is larger than the the complete-data variance,
because of the information lost due to the missing data, and this makes it
an appropriate variance (Carpenter et al., 2014; Cro et al., 2015). We point
out that the type I error rate is correct for the repeated sampling variance
and too small for the RR variance, meaning that the RR variance carries a
loss of power: therefore the repeated-sampling variance may be appropriate
for a primary analysis.
In summary, whilst multiple imputation is an attractive and powerful
method for handling missing data in both experimental and observational
studies, it is not always clear what estimand is being targeted or what as-
sumptions are being made about how outcomes for subjects who discontinue
randomised treatment relate to those who remain on study. The recent esti-
mands debate (ICH steering committee, 2014) has led to a growing recogni-
tion that more complex estimation approaches that do not rely on randomi-
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sation are needed to handle post-randomisation events that lead to missing
data, and there are calls for causal inference methods to become more widely
adopted (e.g. Akacha et al. (2016); Little and Kang (2015)). We join this
call to encourage greater understanding and application of ideas from the
causal inference literature to help support the definition and estimation of
estimands of interest in a randomised clinical trial. We hope that this paper
illustrates how a causal inference framework can provide clarity and rigour
in stating estimands, stating assumptions, and performing estimation.
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Appendix A Proof of equation (8)
We first write the de facto estimand at time tmax as a weighted average over
treatment discontinuation times:
E[Ytmax(Da)− Ytmax(0)] =
tmax∑
t=0
αt {µtmax(t|Da = t)− µtmax(0)} (10)
where we define µ(s|Da = s) = E[Y (s)|Da = s] etc.
We next write the terms on the right hand side of (10) for t < tmax using
the result in Table 2:
µtmax(t|Da = t)− µtmax(0) = e
′
tβt(t)
{
µ≤t(t|Da = t)− µ≤t(t)
}
+ e′
t
Kt
{
µ≤t(t)− µ≤t(0)
}
(11)
where et is used to extract the tmaxth element.
Selection effects cancel out over treatment discontinuation times t. To
use this, note that A3 implies
βt(tmax)
{
µ≤t(t|Da = t)− µ≤t(t)
}
= µ>t(tmax|Da = t)− µ>t(tmax)
for each t < tmax, and the sum of the right hand side over t (weighted by
αt) is zero. We sum the left hand side (weighted by αt) and take the last
element, giving
∑
t<tmax
αte
′
tβt(tmax)
{
µ≤t(t|Da = t)− µ≤t(t)
}
+ αtmax {µtmax(tmax|Da = tmax)− µtmax(tmax)} = 0
and hence
αtmaxµtmax(tmax|Da = tmax) = αtmaxµtmax(tmax)
−
∑
t<tmax
αte
′
t
βt(tmax)
{
µ≤t(t|Da = t)− µ≤t(t)
}
. (12)
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Finally, substituting equations (12) and (11) into (10) gives
E[Ytmax(D)− Ytmax(0)] = αtmax {µtmax(tmax)− µtmax(0)}
+
∑
t<tmax
αte
′
t
(βt(t)− βt(tmax))
{
µ≤t(t|Da = t)− µ≤t(t)
}
+
∑
t<tmax
αte
′
tKt
{
µ≤t(t)− µ≤t(0)
}
which is equivalent to equation (8) in the main text.
Appendix B Causal model implementation us-
ing the SAS 5 macros
The modified macro file ‘Part2A 38 causal.sas’ and the HAMD17 data are
available on the DIA section of the website www.missingdata.org.uk. The
HAMD17 data are stored as a SAS data set named Chapter15 example
which we assume has been renamed HAMD.
The modified Part2A macro allows the user to impute under the causal
model by specifying option Method=Causal. The value of k in equation (9)
is specified by Causalk= or defaults to 1 giving the CIR estimate. k can be
specified as a scalar (a constant k for all participants; e.g. Causalk=0.5) or
as a variable that specifies k for each participant (e.g. Causalk=varname).
If k is specified using a variable, that variable must be identified in macro
Part1A using the option id=varname. If Method=Causal is not specified then
RBI methods are implemented and Causalk= is ignored.
Causal model (5) with k0 = 0.5 can be fitted to the HAMD17 data by:
%Part1A(Jobname=Example, Data=HAMD, Subject=Patient, Response=Change,
Time=Visit, Treat=Therapy, Catcov=PoolInv, Covbytime=Basval,
Covgroup=Therapy);
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%Part1B(Jobname=Example, Ndraws=100, Thin=100, Seed=12345);
%Part2A(Jobname=Example_causal, Inname=Example, Method=Causal,
Causalk=.5, Ref=Placebo, VCMethod=Ref);
The option Covgroup=Therapy in the %Part1A call specifies that the
variance-covariance matrix is estimated separately by arm, but Catcov=PoolInv
and Covbytime=Basval specify that the coefficients of the baseline covariates
are assumed equal across arms.
Causal model (6) with k1 = 0.5 can be fitted to the HAMD17 data after
creating a new variable k1power to hold the individual’s value of kvs−vt1 where
s = tmax and t = Da. In these data Visit is coded 0, 4, 5, 6, 7, so we set
vs = 7 and compute vt as the last value of Visit:
proc sql;
create table HAMD2 as
select *, 0.5**(7-max(Visit)) as k1power
from HAMD
group by Patient;
quit;
Although k1power is computed for all individuals, the next steps ignore
values computed in the Z = c arm:
%Part1A(Jobname=Example, Data=HAMD2, Subject=Patient, Response=Change,
Time=Visit, Treat=Therapy, Catcov=PoolInv, Covbytime=Basval,
Covgroup=Therapy, Id=k1power);
%Part1B(Jobname=Example, Ndraws=100, Thin=100, Seed=12345);
%Part2A(Jobname=Example_causal, Inname=Example, Method=Causal,
Causalk=k1power, Ref=Placebo, VCMethod=Ref);
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%Part1A and %Part1B need not be repeated for different values of k0 or
k1. The imputed data sets in either case are analysed using
%Part2B(Jobname=Example_causal, Seed=54321);
%Part3(Jobname=Example_causal, Anref=Placebo,
Label=Causal with sigma from reference);
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Table 1: Notation.
Notation Explanation
Z Randomised treatment arm: Z = a for the
active treatment and Z = c for the control
treatment.
Da or Dc Participant’s last observation time prior to
stopping treatment in arm a or c.
Yt Response at time t, where t = 0, ..., tmax.
Y = (Y ≤t,Y >t) The vector of all outcomes from t = 0 to
t = tmax, with subvectors for outcomes until
time t, and for outcomes from time t+ 1.
Yt(s) Potential outcome at time t if s periods of the
active treatment were received, where 0 ≤
s ≤ tmax.
Y (s) = (Y ≤t(s),Y >t(s)) The vector of all potential outcomes if s pe-
riods of the active treatment were received,
with subvectors for outcomes until time t,
and for outcomes from time t+ 1.
µ(s) Vector of overall means of counterfactuals if
participants would receive only s periods of
the active treatment.
Σ(s) Variance-covariance matrix of var (Y (s)) for
s = 0, tmax.
βt(s) Regression coefficient of Y >t(s) on Y ≤t(s)
for s = 0, tmax.
Σ>t>t|≤t(s) Residual variance of Y >t(s) given Y ≤t(s) for
s = 0, tmax.
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Table 2: Mean of the imputation distribution of Y >t(t) for t < tmax given
randomisation Z = a, past Y ≤t and treatment discontinuation time Da = t,
under various reference-based imputation methods (Carpenter et al., 2013)
and the proposed causal model.
Method Mean of the imputation distribution
Reference-based imputation methods
LMCF βt(tmax)
{
Y ≤t − µ≤t(t)
}
+Ctµ≤t(t)
J2R* βt(0)
{
Y ≤t − µ≤t(t)
}
+µ>t(0)
CIR* βt(0)
{
Y ≤t − µ≤t(t)
}
+Ct
{
µ≤t(t)− µ≤t(0)
}
+µ>t(0)
CR* βt(0)
{
Y ≤t − µ≤t(t)
}
+βt(0)
{
µ≤t(t)− µ≤t(0)
}
+µ>t(0)
Causal model βt(t)
{
Y ≤t − µ≤t(t)
}
+Kt
{
µ≤t(t)− µ≤t(0)
}
+µ>t(0)
*with control arm as the reference and variance-covariance from the control arm
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Table 3: Simulation study: estimates of treatment effect at the final visit
using complete data, causal model imputation and RBI imputation. β1(0) =
(0, 0.5)′ in all cases. β1(2) 6= β1(0) means β1(2) = (−0.12, 0.74)
′.
Data generating mechanisms for observed data
MCAR MAR
β1(2) = β1(0) β1(2) 6= β1(0) β1(2) = β1(0) β1(2) 6= β1(0)
A. Complete data generated with:
β1(1) = β1(0)
k = 0.00 0.99 0.99 1.00 0.70
k = 0.50 1.24 1.24 1.25 0.95
k = 0.74 1.36 1.36 1.37 1.07
k = 1.00 1.49 1.49 1.50 1.20
β1(1) = β1(2)
k = 0.00 0.99 1.00 1.00 1.00
k = 0.50 1.24 1.25 1.25 1.25
k = 0.74 1.36 1.37 1.37 1.37
k = 1.00 1.49 1.50 1.50 1.50
B. Causal model imputation with assumed β˜1(1) and k˜
β˜1(1) = β1(0)
k˜ = 0.00 1.00 1.00 1.00 0.71
k˜ = 0.50 1.24 1.25 1.25 0.96
k˜ = 0.74 1.36 1.37 1.37 1.08
k˜ = 1.00 1.49 1.50 1.50 1.21
β˜1(1) = β1(2)
k˜ = 0.00 1.00 1.00 1.00 1.00
k˜ = 0.50 1.24 1.25 1.25 1.25
k˜ = 0.74 1.36 1.37 1.37 1.37
k˜ = 1.00 1.49 1.50 1.50 1.50
C. RBI imputation with assumed variance-covariance and method
Variance-covariance matrix from control arm
J2R 1.00 1.00 1.00 0.71
CR 1.24 1.25 1.25 0.96
CIR 1.49 1.50 1.50 1.21
Variance-covariance matrix from active arm
J2R 1.00 1.00 1.00 1.00
CR 1.24 1.37 1.25 1.38
CIR 1.49 1.50 1.50 1.50
Note: Maximum Monte Carlo standard error < 0.01
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Table 4: Simulation study: average standard error (empirical standard error)
for the treatment difference at the final visit using complete data, causal
model imputation and RBI imputation. β1(0) and β1(2) as in Table 3.
Data generating mechanisms for observed data
MCAR MAR
β1(2) = β1(0) β1(2) 6= β1(0) β1(2) = β1(0) β1(2) 6= β1(0)
A. Complete data generated with:
β1(1) = β1(0)
k = 0.00 0.276 (0.273) 0.318 (0.311) 0.260 (0.255) 0.295 (0.288)
k = 0.50 0.272 (0.269) 0.315 (0.308) 0.261 (0.256) 0.298 (0.291)
k = 0.74 0.302 (0.206) 0.342 (0.247) 0.311 (0.219) 0.351 (0.258)
k = 1.00 0.270 (0.266) 0.313 (0.306) 0.262 (0.257) 0.301 (0.295)
β1(1) = β1(2)
k = 0.00 0.276 (0.273) 0.318 (0.316) 0.260 (0.255) 0.292 (0.288)
k = 0.50 0.272 (0.269) 0.315 (0.312) 0.261 (0.256) 0.296 (0.291)
k = 0.74 0.271 (0.268) 0.314 (0.311) 0.262 (0.256) 0.298 (0.294)
k = 1.00 0.270 (0.266) 0.313 (0.310) 0.262 (0.257) 0.300 (0.296)
B. Causal model imputation with assumed β˜1(1) and k˜
β˜1(1) = β1(0)
k˜ = 0.00 0.310 (0.168) 0.337 (0.189) 0.305 (0.171) 0.328 (0.181)
k˜ = 0.50 0.301 (0.190) 0.327 (0.226) 0.299 (0.189) 0.322 (0.214)
k˜ = 0.74 0.302 (0.206) 0.327 (0.249) 0.301 (0.206) 0.325 (0.237)
k˜ = 1.00 0.305 (0.226) 0.332 (0.277) 0.306 (0.227) 0.332 (0.267)
β˜1(1) = β1(2)
k˜ = 0.00 0.310 (0.168) 0.359 (0.187) 0.315 (0.188) 0.359 (0.206)
k˜ = 0.50 0.301 (0.190) 0.344 (0.224) 0.310 (0.204) 0.350 (0.236)
k˜ = 0.74 0.302 (0.206) 0.342 (0.247) 0.311 (0.219) 0.351 (0.258)
k˜ = 1.00 0.305 (0.226) 0.345 (0.275) 0.316 (0.239) 0.356 (0.285)
C. RBI imputation with assumed variance-covariance and method
Variance-covariance matrix from control arm
J2R 0.310 (0.168) 0.337 (0.189) 0.305 (0.171) 0.328 (0.181)
CR 0.303 (0.192) 0.328 (0.229) 0.306 (0.200) 0.331 (0.226)
CIR 0.305 (0.226) 0.332 (0.277) 0.306 (0.227) 0.332 (0.267)
Variance-covariance matrix from active arm
J2R 0.310 (0.168) 0.359 (0.187) 0.315 (0.188) 0.359 (0.206)
CR 0.305 (0.192) 0.344 (0.249) 0.332 (0.236) 0.370 (0.283)
CIR 0.305 (0.226) 0.345 (0.275) 0.316 (0.239) 0.356 (0.285)
Note: Maximum Monte Carlo standard error < 0.0005
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Table 5: HAMD17 and pain score data: estimated treatment effect at the
final visit using standard multiple imputation with 100 imputations, mixed
model for repeated measures (MMRM) and RBI methods.
Estimand & HAMD17 Pain score
Method Estimate1 Std. error p-value Estimate2 Std. error p-value
De jure
Standard MI -2.62 0.99 0.01 -0.88 0.39 0.03
MMRM -2.58 1.03 0.01 -0.88 0.39 0.03
De facto
RBI1: variance-covariance from the placebo arm
J2R -2.01 1.01 0.05 -0.64 0.40 0.11
CR -2.22 0.99 0.03 -0.75 0.39 0.06
CIR -2.30 0.99 0.02 -0.77 0.39 0.05
RBI2: variance-covariance from the drug arm
J2R -1.99 1.01 0.05 -0.60 0.39 0.13
CR -2.20 0.99 0.03 -0.71 0.39 0.07
CIR -2.28 0.99 0.02 -0.73 0.39 0.06
1 Monte Carlo standard error for MI methods is ≤ 0.04.
2 Monte Carlo standard error for MI methods is ≤ 0.02.
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Figure 1: HAMD17 and pain score data sets: observed mean profile according
the time at which treatment discontinued in the drug and placebo arms.
6(7%)
5(6%) 9(11%)
64(76%)
7(8%)
5(6%)
11(12%)
65(74%)
−
9
−
7
−
5
−
3
−
1
1
−
9
−
7
−
5
−
3
−
1
1
4 5 6 7
Drug
Placebo
HAMD 17
M
ea
n 
ch
an
ge
s 
fro
m
 th
e 
ba
se
lin
e
Study week
3(4.5%)
1(1.5%)
5(7.5%)
5(7.5%)
47(70%)
2(3%)
1(2%)
2(4%)
7(13%)
2(4%)
4(7%)
36(67%)
−
2
−
1
0
1
2
3
4
5
6
−
2
−
1
0
1
2
3
4
5
6
2 4 6 8 10 12
Drug
Placebo
Study week
Pain score
Note: In the pain score data, four subjects in the drug arm and two subjects in the placebo
arm did not complete any post-baseline visit and were excluded from analysis.
37
Figure 2: HAMD17 and pain score data sets: tipping point analysis for
the estimated treatment effect at the final visit using causal model (5) with
sensitivity parameter k0. The horizontal solid and dotted lines represent the
treatment estimates and their pointwise 95% CI, respectively. The vertical
solid line corresponds to k0 such that p-value > 0.05 in the left hand side of
the line (tipping point).
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Figure 3: HAMD17 and pain score data sets: tipping point analysis for
the estimated treatment effect at the final visit using causal model (6) with
sensitivity parameter k1. The horizontal solid and dashed lines represent the
treatment estimates and their pointwise 95% CI, respectively. The tipping
point is not attained in the range 0 ≤ k1 ≤ 1.
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